Introduction: Short stature is the most common physical abnormality in Turner syndrome (TS), with adult stature averaging 20 cm shorter compared to the general population.
Aim: To study the efficiency of early initiation for GH therapy on final stature for patients with Turner syndrome and to prove its important role in obtaining optimal growth rates.
Methods: We studied a lot of 24 patients with TS diagnosed and followed up in our Department of Endocrinology. The most frequently congenital malformations associated with Turner syndrome were:
Congenital heart diseases (seven cases), Hypothyroidism (five cases) and Structural malformations of the kidneys (five cases).
Considering the diagnosis age for Turner syndrome, four categories were defined: i) 05 years: 5% (two patients), ii) 510 years: 36% (eight patients), iii) 1015 years: 36% (eight patients), iv) 1520 years: 23% (six patients). Recombined GH therapy was initiated for the last three categories.
Results: The growth rates were significant in the three groups:
i)age 510 years: average growth rate: 0.736 cm/month (18 months follow-up); average initial stature: 113.3 cm; mean total height gain:11.7 cm
ii)age 1015 years: average growth rate:0.561 cm/month (mean follow-up 24 months); average initial stature: 124.6 cm; mean total height gain: 15.0 cm
iii)age 1520 years: average growth rate:0.278 cm/month (mean follow-up 18 months); average initial stature 137.6 cm; mean total height gain: 4.6 cm
Conclusions: Comparing the growth curves and growth velocity in the three groups we notice that growth rates decrease with late therapy initiation, which becomes an important factor for the final stature prognosis. Longer follow-up is important for evaluating the efficiency of early initiated GH therapy.
Discussion: In patients group of 1520 years, we obtained the lowest growth rates, the incriminated factor being the associated substitutive oestrogen therapy and its effects on the bone plate.
27 Apr - 01 May 2013
European Society of Endocrinology